Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
1994-01-27
2003-07-01
Allen, Marianne P. (Department: 1631)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000, C530S351000, C530S399000, C530S412000, C530S413000, C530S416000, C530S417000
Reexamination Certificate
active
06586394
ABSTRACT:
BACKGROUND OF THE INVENTION
Bichel [Bichel, Nature 231: 449-450 (1971)] reported that removing most of the tumor from mice bearing ascites tumors at a plateau of tumor growth was followed by a marked increase in the growth of the remaining tumor cells. Injection of cell-free ascites, obtained from mice bearing fully developed ascites tumors, into mice with growing ascites tumors resulted in a pronounced inhibition of ascites growth. Bichel, supra, also observed that two surgically joined mice (parabiotic), one mouse with an advanced tumor and the other with an early tumor, resulted in a pronounced inhibition of growth of the early tumor. Based upon these observations, [Bichel, Europ. J. Cancer 6: 291-296 (1970) and Bichel, supra] the existence of a diffusible inhibitory principle which circulated through the peritoneum of the parabiotic mice and was present in the cell-free ascites fluid produced by the fully developed ascites tumors was postulated. The nature of this inhibiting principle was not characterized, but it was speculated that the rate of growth of the ascites tumors was dependent upon the amount of tumor tissue and was determined by the amount of inhibitory principle produced.
Substances having tumor growth inhibitory activity have been described. [Holley, et al., Proc. Natl. Acad. Sci. USA 77:5989 (1980) and Holley, et al., Cell Biol. Int. Reports 7: 525-526 (1983)]. These publications report the isolation from African green monkey BSC-1 cells of a growth inhibitory substance which inhibited the growth of BSC-1 cells, human mammary tumor cells and normal human mammary cells. This substance has recently [Tucker, et al., Science 226: 705-707 (1984): Roberts, et al. Proc. Natl. Acad. Sci. 82 (Jan): 119-123 (1985)] been shown to be identical, or highly related, to a 25,000 dalton two chain human platelet-derived polypeptide designated &bgr;-TGF (Assoian, et al., J. Biol. Chem. 258: 7155-7160 (1983)]. Independently, McMahon, et al. [Proc. Natl. Acad. Sci. USA 79, 456-460 (1982)] have purified from rat liver a 26,000 dalton substance which inhibits the proliferation of nonmalignant rat liver cells, but does not inhibit the proliferation of malignant rat liver cells. Other growth inhibitory substances have been identified in cultured chick spinal cord cells [Kagen, et al., Experimental Neurology 58: 347-360 (1970); Harrington, et al., Proc. Natl. Acad. Sci. USA 77: 423-427 (1980) and Steck, et al. J. Cell Biol. 83: 562-575 (1979)].
Iwata, et al., [J. Cellular Biochem. Supp. 5: 401 (1982)] previously described a microtiter plate system for assaying growth stimulation and growth inhibition activity. Todaro, et al. [Todaro, et al., in
Tumor Cell Heterogeneity; Origins and Implications,
Bristol-Myers Cancer Symposia, Volume 4, Owens, A. H., Coffey, D. S., and Baylin, S. B., Eds. (Academic Press, 1982), pp. 205-224)] and Iwata, et al. [Fed. Proc. Fed. AM. Soc. Exp. Biol. 42: 1833 (1983)] previously reported the isolation of tumor inhibitory activity from tissue culture fluids of human tumor cells propagated in culture. The observations described in these reports were preliminary and little detail was provided.
On Apr. 20, 1984, a patent application was filed with the United States Patent and Trademark Office under U.S. Ser. No. 602,520, entitled “Substantially Purified Tumor Growth Inhibitory Factor (TIF)” on which one of us, Kenneth K. Iwata, is named as coinventor. This application concerns the preliminary identification of a not well-defined substance or substances present in, and derived from, human tumor cells propagated in culture. This substance or substances resembles the tumor inhibitory activity previously reported. [Todaro, et al., in
Tumor Cell Heterogeneity; Origins and Implications,
Bristol-Myers Cancer Symposia, Volume 4, Owens A. H., Coffey, D. S., and Baylin, S. B., Eds. (Academic Press, 1982), pp. 205-224); Iwata, et al., Fed. Proc. Fed. Am. Soc. Exp. Biol. 42: 1833 (1983].
Todaro [Todaro, G. J. in
Epigenetic Regulation of Cancer,
Terry Fox Cancer Research Conference (University of British Columbia; Vancouver, B.C., Canada) Abs. 13 (1984)] recently reported two factors with tumor cell growth inhibitory properties which were reportedly sequenced and shown to consist of 70 and 90 amino acid residues, respectively. Neither the source, i.e. cell, tissue type of species, or the method of purification of the factors were disclosed.
SUMMARY OF THE INVENTION
This invention is directed to a chromatographically recovered polypeptide having the N-terminal amino acid sequenceAla-Leu-Asp-Thr-Asn-Tyr-Cys-Phe-Arg-Asn-Leu-Glu-Glu-Asn-Cys-Cys-Val. This polypeptide is known as TGI, TGI-1 and TGI-2. It is also referred to as TGF-&bgr;3. The invention is also directed to a compositions which comprises the chromatographically recovered polypeptide. The invention also provides a pharmaceutical compositions to inhibit the growth of epithelial cells or heal a wound or treat a burn consisting of the chromatographically recovered polypeptide. The invention is also directed to methods which comprise administering to a subject an effective amount of the chromatographically recovered so as to thereby inhibit the growth of epithelial cells, or heal the wound or treat the burn.
REFERENCES:
patent: 4434094 (1984-02-01), Seyedin et al.
patent: 4708948 (1987-11-01), Iwata et al.
patent: 4774228 (1988-09-01), Seyedin et al.
patent: 4774322 (1988-09-01), Seyedin et al.
patent: 4886747 (1989-12-01), Derynck et al.
patent: 5104977 (1992-04-01), Sporn et al.
patent: 136093 (1985-04-01), None
patent: 159289 (1985-10-01), None
patent: 271211 (1986-06-01), None
patent: 86298432 (1986-12-01), None
patent: 8404924 (1984-12-01), None
Derynck et al. (Nature) vol. 316: pp 701-705, Aug. 22, 1985.*
Stewart et al. (1996) Umbilical Cord Transforming Growth Factor-&bgr;3: Isolation, Comparison with Recombinant TGF-&bgr;3 and Cellular Localization, Growth Factors 13;87-98.
Bhown, A.S. and Bennett, J.C. (1983) High-sensitivity Sequence Analysis of Proteins Recovered from Sodium Dodecyl Sulfate Gels, Methods in Enzymology 91:450-455.
A.B. Roberts, et al. (1985) Proc. Natl. Acad. Sci.; 82: 119.
Frolik C. et al., (1983) PNAS, 80: 3676-3680.
Roberts A. et al., (1980) PNAS, 77: 3494-3498.
Iwata K., (1983) Fed. Proc. Am. Soc. Exp. Biol., 42: 1833 Abst. 442.
Davoren P., (1983) Biochemical Biophysical Acta, 63: 150-153.
Gold Leslie I.
Iwata Kenneth K.
Stephenson John R.
Allen Marianne P.
OSI Pharmaceuticals, Inc.
White John P.
LandOfFree
Tissue-derived tumor growth inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue-derived tumor growth inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue-derived tumor growth inhibitor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3024612